Breaking Finance News

Kura Oncology Inc (NASDAQ:KURA) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has upgraded Kura Oncology Inc (NASDAQ:KURA) to Hold in a statement released on 10/12/2016.

Having a price of $5.56, Kura Oncology Inc (NASDAQ:KURA) traded -2.63% lower on the day. With the last close up 33.38% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Kura Oncology Inc has recorded a 50-day average of $6.13 and a two hundred day average of $4.17. Volume of trade was down over the average, with 41,098 shares of KURA changing hands under the typical 306,260

Performance Chart

Kura Oncology Inc (NASDAQ:KURA)

With a total market value of $0, Kura Oncology Inc has with a one year low of $2.50 and a one year high of $25.00 .

A total of 4 analysts have released a report on Kura Oncology Inc. zero analysts rating the company a strong buy, zero analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $18.00.

More About Kura Oncology Inc (NASDAQ:KURA)

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.